290650 — L&C Bio Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeMid CapMomentum Trap

Market Cap
KR₩2tn
Enterprise Value
KR₩2tn
Revenue
KR₩85bn

Annual income statement for L&C Bio Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	R2023 December 31st	R2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	45,677	52,572	65,927	72,032	85,476
Cost of Revenue
Gross Profit	28,450	26,992	33,856	35,676	45,389
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	32,503	43,048	60,173	68,181	153,737
Operating Profit	13,174	9,524	5,754	3,852	-68,260
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	17,095	4,563	63,266	139,822	-160,034
Provision for Income Taxes
Net Income After Taxes	15,580	5,692	48,859	144,939	-138,357
Minority Interest
Net Income Before Extraordinary Items
Extraordinary Items
Net Income	13,814	4,544	48,361	141,596	-138,175
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	13,814	4,544	51,826	141,596	-138,175
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	618	197	2,176	6,354	-3,826
Dividends per Share